Belumosudil for lung transplant patients at risk of chronic rejection
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests whether the drug Belumosudil can help prevent chronic lung rejection in people who recently had a lung transplant and showed signs of early rejection. It may improve long-term lung health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 years or older and have received a lung transplant.
- A biopsy taken 2 to 25 months after your transplant must show signs of early rejection or lung injury.
- You must be willing to use effective birth control during the study and for 3 months after.
- Your blood counts and liver/kidney function must meet specific levels (checked within 30 days of joining).
- You cannot have active infections like CMV, HIV, or hepatitis B/C.
- Your maintenance anti-rejection medication must include a calcineurin inhibitor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called emapalumab for people who have a sudden drop in lung function after a lung transplant. The drug targets a protein that may be causing the damage, and the goal is to treat this reaction safely.
This study tests whether the drug tocilizumab can help prevent your body from rejecting a new lung after transplant. It might help improve the success of your transplant by reducing immune system activity.
This trial tests a pill called belumosudil to see if it can help people with chronic graft-versus-host disease (a common complication after a stem cell transplant where donor cells attack your body). It is for patients who have symptoms but are not yet on strong immune-suppressing drugs.
This study tests a new medicine called belumosudil for children with chronic graft-versus-host disease (GVHD) that hasn't improved with at least 2 other treatments. The goal is to see if it can help control the disease and improve symptoms.
This study looks at ways to improve outcomes for people who are waiting for or have recently received a lung transplant. It aims to find better management strategies for both donors and recipients.
This trial tests an oral medication called belumosudil for people with chronic lung allograft dysfunction (CLAD) after a double lung transplant. It may help slow the decline in lung function.
Hear when a new Lung Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.